Endocervical prostaglandin E2 gel for preinduction cervical softening

Area of Science:

• Obstetrics and Gynecology
• Reproductive Medicine
• Pharmacology

Background:

• Cervical ripening is crucial for labor induction in term pregnancies.
• Prostaglandin E2 (PGE2) is a common agent for cervical softening.
• Low Bishop scores indicate unfavorable cervical conditions for induction.

Purpose of the Study:

• To evaluate the safety and efficacy of a new endocervical prostaglandin E2 (PGE2) gel for preinduction cervical softening.
• To compare the new PGE2 gel with a PGE2 vaginal tablet and placebo in nulliparous women.

Main Methods:

• A randomized, double-blind study involving nulliparous women at term with low Bishop scores.
• Single endocervical application of 0.5 mg PGE2 gel, 2.0 mg PGE2 vaginal tablet, or placebo.
• Success defined as a ≥3-point increase in Bishop score within 12 hours.

Main Results:

• Overall success rates were 55% for the PGE2 gel, 37% for the PGE2 tablet, and 20% for placebo.
• In women with very unfavorable cervix (Bishop score 0-2), success rates were 75% for gel, 15% for tablet, and 0% for placebo.
• The PGE2 gel demonstrated a very low incidence of side effects.

Conclusions:

• The new endocervical PGE2 gel is a safe and effective option for preinduction cervical softening, particularly in women with unfavorable cervical conditions.
• The gel outperformed both the PGE2 vaginal tablet and placebo in improving Bishop scores.
• Further multi-center trials are recommended to confirm these findings.